CURE.X
CURE.X

Biocure Technology Inc.

Status
Active
Issued & Outstanding10,444,504
Reserved for Issuance884,059
Currency
CSE Index

About

Biocure Technology Inc.

Listing Date
May 10, 2010
Social

Biocure Technology Inc. is a biopharmaceutical company, specializing in the development and commercialization of major biosimilar products. Biocure is currently conducting pre-clinical trials of its biosimilar candidates of Interferon Beta 1b, PEG-Filgrastim and Ranibizumab as well as CAR-T Cell Therapy.